Along the lines of Buzz’s comment, I would like to see STAT be more careful about attacking small biotech companies. There are certain other STAT authors who are somewhat infamous for this habit (not this author). These small companies are often trying new approaches and they don’t need extra criticism for it to scare away investors. The seed for the next Alzheimer’s drug may very well originate from a small biotech that is easy to criticize in the early stages.
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology